We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Cormorant Pharmaceuticals Acquired by BMS for $520M

Cormorant Pharmaceuticals Acquired by BMS for $520M

Cormorant Pharmaceuticals Acquired by BMS for $520M

Cormorant Pharmaceuticals Acquired by BMS for $520M

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cormorant Pharmaceuticals Acquired by BMS for $520M"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bristol-Myers Squibb (BMS) has acquired Cormorant Pharmaceuticals, a developer of cancer and rare-disease therapies, for up to $520 million, in a deal designed to broaden the buyer’s oncology pipeline, the companies said today.

The deal gives BMS full rights to Cormorant’s HuMax-IL8 antibody program and lead candidate HuMax-IL8, a Phase I/II monoclonal antibody targeted against interleukin-8 (IL-8).

By targeting IL-8, HuMax-IL8 offers the potential to enhance immune response and increase the efficacy of existing cancer medicines through combination therapy, BMS and Cormorant reason, adding that the antibody candidate can complement T-cell-directed antibodies and co-stimulatory molecules.

“We believe combination therapy will be foundational to delivering the potential for long-term survival for patients, and the opportunity to develop the HuMax-IL8 antibody program together with our broad Immuno-oncology pipeline enables us to accelerate the next wave of potentially transformational immunotherapies,” Francis Cuss, MB BChir, FRCP, evp and CSO, BMS said in a statement.

As of May 1, according to its website, BMS’ immuno-oncology portfolio includes three marketed treatments—Opdivo® (nivolumab), Empliciti™ (elotuzumab) and Yervoy® (ipilimumab)—and a pipeline anchored by the Phase III candidate Prostvac with five Phase I candidates.

BMS’ cancer holdings also include the marketed small-molecule drug Sprycel® (dasatinib) and five Phase I candidates.

“Bristol-Myers Squibb’s rich pipeline of clinical candidates and approved products provides even more opportunity for potential therapeutic synergy when coupled with HuMax-IL8,” added Cormorant CEO Maarten de Château, M.D., Ph.D.

Cormorant acquired exclusive worldwide rights to HuMax-IL8 from Genmab in 2012 in return for an upfront fee and future milestones and royalties, all undisclosed. Genmab in turn acquired the candidate 5 years earlier from Medarex, which BMS acquired in 2009 for $2.4 billion.

On its LinkedIn page, Cormorant stated that HuMax-IL8 is envisioned as a treatment for several forms of cancer since IL-8 is a protein expressed by many solid tumours: “IL-8 inhibition also has the potential to reduce tumour immunosuppression through MDSCs (myeloid-`derived suppressor cells).”

Under the transaction, BMS agreed to pay upfront and near-term milestone payments of up to $95 million, as well as $425 million in additional payments tied to achieving development and regulatory milestones.

The boards of BMS and privately held Cormorant have approved the deal, BMS’ second immuno-oncology effort in as many weeks. On Thursday, BMS and PsiOxus Therapeutics launched an exclusive clinical collaboration to study the combination of Opdivo with PsiOxus Therapeutics’ enadenotucirev in treating a range of tumour types in late-stage cancer patients.